Bing Chen

Dr. Bing Chen

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
MHMengqiang Hu
Mengqiang Hu
BCBing Chen
Bing Chen
YLYuanming Luo
Yuanming Luo
Hemodynamic analysis based on computational fluid dynamics (CFD) modelling is expected to improve risk stratification for patients with aortic aneurysms and dissections. However, the parameter settings in CFD simulations involve considerable variability and uncertainty. Additionally, the exact relationship between hemodynamic features and disease progression remains unclear. These challenges limit the clinical application of aortic hemodynamic models. This review presents a detailed overview of the workflow for CFD-based aortic hemodynamic analysis, with a focus on recent advancements in the field. We also conducted a systematic review of 27 studies with large sample sizes (n > 5) that examine the hemodynamic characteristics of aortic aneurysms and dissections. Some studies identified consistent relationships between hemodynamic features and disease progression, reinforcing the potential for clinical application of aortic hemodynamic models. However, limitations such as small sample sizes and oversimplified patient-specific models remain. These findings emphasize the need for larger, more detailed studies to refine CFD modelling strategies, strengthen the connection between hemodynamics and diseases, and ultimately facilitate the clinical use of aortic hemodynamic models in disease management.

4 April 2022 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
JWJian Wang
Jian Wang
TJTao Jin
Tao Jin
BCBing Chen
Bing Chen
YPYifeng Pan
Yifeng Pan
CSChangming Shao
Changming Shao

20 August 2021 in Frontiers in Medicine
Verified
Journal Article
Open access
ZLZhenjie Liu
Zhenjie Liu
YXYongshan Xu
Yongshan Xu
XXXin Xu
Xin Xu
MHMinzhi He
Minzhi He
PHPan Han
Pan Han
BCBing Chen
Bing Chen
Background: Total percutaneous closure for the site of femoral arterial puncture using Perclose ProGlide (PP) has become prevalent post-percutaneous endovascular aortic repair (EVAR) and veno-arterial extracorporeal membrane oxygenation (VA-ECMO).Objective: To evaluate the safety and efficacy of total percutaneous closure of the femoral artery access site post-EVAR compared with VA-ECMO.Methods: This was a retrospective observational study conducted over 4 years, including 88 patients who underwent EVAR (64 patients) and VA-ECMO (24 patients). Perclose ProGlide devices were used in the femoral artery puncture sites closed percutaneously. In this study, technical success was defined as successful arterial closure of the common femoral artery (CFA) without additional surgical or endovascular procedures to prevent vessel leaking. Access site complications, including overt bleeding requiring transfusion or surgical intervention, minor bleeding, tinea cruris, pseudoaneurysm, and lymphocele, were recorded 24 h and 30 days after arterial closure.Results: Each group's technical success rates were 95.8% (VA-ECMO) and 92.2% EVAR, respectively. There were no differences in the periprocedural complications of major bleeding, pseudoaneurysm, minor bleeding, acute limb ischemia, and groin infection. Furthermore, we did not observe any complications such as arterial thrombosis, dissection, stenosis, arteriovenous fistula, hematoma, groin infection, or lymphocele at the access site by following-up an ultrasound examination. There was no significant difference in the technical success rate of percutaneous closure by the PP device in the EVAR and VA-ECMO oxygenation groups. Also, no periprocedural or 30-day complications were observed at the access site of the EVAR and VA-ECMO patients.


1 August 2025 in Doklady Biochemistry and Biophysics
Verified
Journal Article
Open access
PDF file
WJWei Jin
Wei Jin
JWJue-Jue Wang
Jue-Jue Wang
YFYan-Fei Feng
Yan-Fei Feng
BCBing Chen
Bing Chen
ZHZhao-Hua Hu
Zhao-Hua Hu
Ferroptosis, an iron-dependent form of regulated cell death, represents an emerging therapeutic vulnerability in colorectal cancer (CRC). However, the epigenetic mechanisms controlling ferroptosis sensitivity in CRC remain poorly understood. Here, we identify histone deacetylase 3 (HDAC3) as a pivotal epigenetic suppressor of ferroptosis. Both pharmacological inhibition and genetic knockdown of HDAC3 significantly enhanced ferroptosis sensitivity, as evidenced by elevated intracellular ferrous iron (Fe 2+ ) and lipid peroxidation. Mechanistically, inhibition of HDAC3 reduced the expression of nuclear factor erythroid 2–related factor 2 (NRF2), a master antioxidant transcription factor, thereby leading to downregulation of glutathione peroxidase 4 (GPX4), a central ferroptosis defense gene. Notably, NRF2 knockdown abolished GPX4 downregulation by HDAC3 inhibition, whereas GPX4 overexpression rescued the ferroptotic phenotype caused by HDAC3 depletion. Collectively, these findings define an HDAC3–NRF2–GPX4 axis that suppresses ferroptosis in CRC, and highlight HDAC3 as a potential therapeutic target for ferroptosis-based cancer treatment.